The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation

• Published in: OncoTargets and therapy Vol. 14; pp. 3959 - 3969
• Main Authors: Anekpuritanang, Tauangtham, Uataya, Maythad, Claimon, Apichaya, Laokulrath, Natthawadee, Pongsapich, Warut, Pithuksurachai, Paveena
• Format: Journal Article
• Language: English
• Published: Macclesfield Taylor & Francis Ltd 29.06.2021; Dove
• Subjects: Antibodies; Brain cancer; Cancer therapies; Graves disease; Hospitals; Immunohistochemistry; Kinases; Metastasis; Mutation; Original Research; Otolaryngology; Papillary thyroid carcinoma; Paraffin; Pathology; Patients; Proteins; Sodium; Sodium iodide symporter; Thyroid; Thyroid cancer; Thailand; United States > US; Bangkok Thailand
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S308910

Objective: To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the BRAFV600E mutation. Methods: A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and BRAFV600E mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. Results: The mutated BRAFV600E protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups (P = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma (P = 0.11). Cases with positive NIS expression were likely negative for BRAFV600E mutation (3/4; P = 0.02). Conclusion: Papillary thyroid carcinomas with BRAFV600E mutation were more likely to be negative for NIS expression. BRAFV600E mutation and NIS expressions cannot be used to predict radioiodine sensitivity.